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Low-energy (LE) and high-energy (HE) collisionally activated decompositions (CAD) of
calcium/peptide complexes of the form [M 2 H 1 Ca]1 and [M 1 Ca]21 reflect the site of
calcium binding in various gas-phase peptides that are models of the calcium binding site III
of rabbit skeletal troponin C. The Ca21 binding sites involve an aspartic acid, glutamic acid,
and asparagine, which are in the metal-binding loops of calcium-binding proteins. Both fast
atom bombardment (FAB) and electrospray ionization (ESI) were used to generate the
metal/peptide complexes. When submitted to LE CAD, ESI-produced Ca21/peptide com-
plexes undergo fragmentations that are controlled by Ca21 binding and provide information
on the Ca21 binding site. The LE CAD spectra are simple, indicating that Ca21 binding
involves specific oxygen ligands including acidic side chains and that only a few low-energy
fragmentation channels exist. The HE CAD spectra of FAB-produced Ca21/peptide complexes
are more complex, owing to the introduction of high internal energy into the precursor ion.
Interactions of the other alkaline-earth metal ions Mg21 and Ba21 with these peptides reveal
that the ligand preferences of these metal ions are slightly different than those of Ca21. (J Am
Soc Mass Spectrom 1998, 9, 1020–1028) © 1998 American Society for Mass Spectrometry
Metal ions play a vital role in many biologicalprocesses. They act by triggering mechanisms,stabilizing structure, and controlling redox
behavior [1, 2]. Of all the divalent metallic cations in the
periodic table, calcium plays the most important role in
biology. It acts as a secondary messenger in regulating
numerous intracellular events, taking advantage of its
large membranous concentration gradient. Mediation
of cellular processes by Ca21 ions involves calcium-
binding proteins [3–7]. Various sites in these proteins
vary greatly in their affinities for calcium depending on
amino-acid sequence of the binding site [8]. The calcium
affinities of small peptides with amino-acid sequences
that are models of Ca21 binding sites in proteins were
previously studied in solution [9–11], and the results
show that affinities are modulated by solvent effects.
One motivation for extending these efforts to the gas
phase is that comparison with solution properties
brings understanding of solvent effects. Furthermore,
metal-binding sites in interiors of proteins are hydro-
phobic, and interactions in the gas phase are an appro-
priate model for those in hydrophobic regions [1, 12].
For calcium-binding proteins, the portion that inter-
acts with Ca21 is part of a segment of 12 amino-acid
residues that comprise the polypeptide loop between
the helices [12–14]. The interacting ligands are at rela-
tive positions 1, 3, 5, 7, 9, and 12 of the loop and
generally are carbonyl, carboxyl, and nonaromatic oxy-
gens (e.g., from the side chains of Asp, Asn, Glu, Ser,
and Thr). The calcium binding site III in rabbit skeletal
troponin C has the sequence DRNADG as a part of the
Ca21 binding loop. The x-ray structure of this binding
site reveals that side chains of residues at position 1 (D),
3 (N), and 5 (D) are involved in binding to Ca21 [14].
The goal of our research is to determine by means of
mass spectrometry the metal-binding sites in small
gas-phase peptides that are models for the amino-acid
sequence in large metal-binding proteins. Therefore, we
chose small peptides that are models for Ca21-binding
loops in proteins. We also used the same peptides to
study their intrinsic affinities to calcium, and a descrip-
tion of this work will be published elsewhere [8]. To
determine the important calcium-binding amino acids
and their positions in a peptide chain, low-energy (LE)
and high-energy (HE) collisionally activated decompo-
sitions (CAD) were followed for calcium/peptide com-
plexes introduced into the mass spectrometer as [M 2
H 1 Ca]1 and [M 1 Ca]21. The Ca21-containing mo-
nopositive ions were produced by fast atom bombard-
ment (FAB) or electrospray ionization (ESI), whereas
complexes of the neutral peptide with the divalent
metal ion require ESI [15, 16]. We also describe interac-
tions of the alkaline-earth metal ions Mg21 and Ba21
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with the peptides and compare the results with those
involving Ca21.
In previous reports of intrinsic interactions of alka-
line-earth metal ions and peptides, emphasis was given
to opportunities for sequencing and for examining
general interactions but not for investigating peptides
that are models for binding in solution [17–19]. Other
previous studies of alkaline-earth metal ions were of
triply deprotonated tripeptides [20, 21] and showed
that the interactions are strong and that the fragmenta-
tions characterize the amino acids at the N terminus.
Experimental
Reagents
The peptides used for this work were synthesized at the
Washington University, Department of Pathology by
automatic, stepwise, solid-phase peptide synthesis us-
ing Fmoc-protected amino acids. The crude peptides
were released from the resin by ammonolysis, to give a
C-terminal amidated species and purified by reverse-
phase high-performance liquid chromatography
(HPLC) using a C-18 column, and fractions were col-
lected and lyophilized. The identity of the peptides was
confirmed by FAB mass spectrometry and tandem mass
spectrometry of the [M 1 H]1 ions.
The cation-exchange resins (AG 50W-X8, mesh size:
200–400 mm) were purchased from the Bio-Rad Labo-
ratories (Hercules, CA) in the H form. Conversion to
Ca21-saturated resins was achieved by washing the H
form with five-bed volumes of ;8 M calcium acetate.
Any residual Ca(OAc)2 solution was washed out by
flushing the resin with three-bed volumes of deionized
water (1018 V cm) [22].
Instrumentation
Mass spectrometric experiments were performed on a
VG ZAB-T (Manchester, UK) four-sector and a Finnigan
LCQ (San Jose, CA) ion-trap mass spectrometer. The
former consisted of two-high mass, double-focusing
mass spectrometers of BEBE design. The instrument
was operated at an accelerating voltage 8 kV, and FAB
was accomplished with Cs1 ions from a gun that
provided a 22-keV Cs1 beam (the overall energy for
desorption was 30 kV). FAB mass spectra were acquired
by using the first stage (MS-1) at a mass resolving
power of approximately 1200 (10% valley depth). The
second stage (MS-2), which was a reverse-geometry,
Mattauch–Herzog type instrument with a planar elec-
trostatic analyzer, was used to obtain product-ion mass
spectra after selecting the precursor ions with MS-1 and
activating them by collisions in a cell containing helium
gas at pressures sufficient to give 50% main-beam
suppression. The fragment ions formed in the third-
field-free region were detected by a single-point detec-
tor. The collision cell was floated at 4 kV.
For HE CAD of ESI-produced [M 1 Ca]21 ions, the
VG-ZAB-T instrument was equipped with a VG ESI
source. The ESI needle was at 8120 V, the sampling cone
at 4200 V, and the ring electrode at 4120 V. Nitrogen
was used as a bath and nebulizer gas at flow rates of 400
and 12 L/h, respectively. Sufficient peptide was dis-
solved in 80/20 water/methanol containing 0.1 mM
calcium acetate to give a final concentration of 20 mM,
and the solutions was continuously infused to the
needle by using a Harvard model 22 syringe pump
(Harvard Apparatus, South Natick, MA) at a flow rate
10 mL/min. In tandem mass spectrometry (MS/MS)
experiments, fragment ions were collected on an array
detector. Data acquisition was carried out with a VG
OPUS V 3.1X data system, which was interfaced to the
mass spectrometer by a VG SIOS I unit.
LE CAD experiments were carried out with a Finni-
gan LCQ ion-trap mass spectrometer equipped with an
electrospray-ionization source. All samples were intro-
duced at a flow rate of 10 mL/min. The spray needle
was held at 4.2 kV, and a 4.4 3 105 Pa coaxial flow of
nitrogen was used to stabilize the spray. A heated (200°C)
stainless steel capillary served as the counterelectrode
and was held at 13.5 V. In all experiments, helium was
introduced to a pressure of 1 mtorr (measured by a
remote ion gauge) for improving the trapping efficiency
of the ion trap. The background helium gas also served
as the collision gas during the CAD event. Collisional
activation of the ions, which were excited by a “tickle”
voltage applied to the end caps (20 eV), proceeded via
multiple, low-energy collisions with helium.
A typical experimental sequence consisted of ion-
injection times of 100–300 ms, and ion detection using
the mass-selective instability mode at a scan rate of 5000
u/s. Ions were detected at a 15-kV conversion dynode
supported by a channeltron electron multiplier. A
80/20 mixture of water/methanol was used as the
carrier solvent.
Results and Discussion
Formation of the Ca21/Peptide Complexes
Ca21/peptide complexes were produced by both FAB
and ESI. To form the [M 2 H 1 Ca]1 ions under FAB
conditions, a 1-mL aliquot of a 1-mg/mL peptide solu-
tion was mixed with the 3-NBA matrix and several
beads of calcium-saturated cation-exchange resin on a
FAB sample probe [23]. Under ESI conditions, singly
charged [M 2 H 1 Ca]1 and doubly charged [M 1
Ca]21 ions were produced when a mixture of peptide
and 0.1 mM calcium-acetate solution was sprayed in a
20:80 MeOH:H2O solvent system; [M 1 H]
1 and [M 1
2H]21 ions were also observed under these conditions.
The relative abundances of these various ions depend
on pH, the solvent composition, amino-acid sequence,
and amino-acid type. We optimized the conditions for
producing abundant Ca21/peptide ions. Basic condi-
tions favor formation of singly charged [M 2 H 1 Ca]1
ions because deprotonation of the peptide must be
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promoted. Under neutral conditions (no acid or base
added), production of doubly charged [M 1 Ca]21 ions
is favored because preserving the peptide as a neutral
species is required. Under acidic conditions, protona-
tion of the peptide is a major process, competitive
binding to Ca21 is diminished, and production of
protonated species is favored.
The amino-acid sequence in the peptides also influ-
ences the relative abundances of the ions. Incorporation
of additional acidic residues (e.g., aspartic acid) in the
peptide causes the [M 2 H 1 Ca]1 and [M 1 Ca]21 ions
to be more abundant at neutral pH than the [M 1 H]1
and [M 1 2H]21 ions, whereas for peptides in which an
amino acid was changed from basic to neutral to acidic
(e.g., from DRNADG to DANADG to DENADG), the
abundances of [M 1 H]1 and [M 1 2H]21 ions de-
creased by a factor of approximately 30%, whereas the
[M 2 H 1 Ca]1 abundance increased tenfold and that
of [M 1 Ca]21 increased by approximately 30%. Re-
moval of basic residue (e.g., arginine) from the peptide
sequence leads to elimination of a major protonation
site, favoring deprotonation of the peptide and Ca21
binding.
Low Energy CAD of ESI-Produced Ions
LE CAD of [M 2 H 1 Ca]1 ions. Upon low-energy col-
lisional activation, the Ca21/peptide complexes frag-
ment to give remarkably simple spectra of product ions;
most product ions observed under LE CAD are pre-
sented in Table 1. The principal fragmentation pathway
is typically loss of water followed by the loss of ammo-
nia or, in some case, vice versa. The simplicity of the
spectra shows that only a few low-energy fragmenta-
tion channels are open for the decomposition Ca21/
peptide complexes, suggesting that there is strong bind-
ing between Ca21 and a substantial portion of the
peptide. For example, the calcium complex of peptide
NRDADA (m/z 698) decomposes to give, besides
major H2O and NH3 losses, small abundances of b*5, y*5,
[y*5 2 H2O], y*4, c*4, [c*4 2 H2O] calcium-containing, and c2
and b2 noncalcium product ions (Figure 1). To keep the
nomenclature of product ions simple, we omit the metal
from the labels and designate product ions as if they
were formed from protonated precursors; those ions
that contain Ca21 are designated by an p in their labels.
For example, a b*n ion is [bn 2 2H 1 Cat]
1, c*n is [cn 2
2H 1 Cat]1, and y*n is [yn 2 2H 1 Cat]
1.
Product ions, which contain either the N or the C
terminus, are formed by losses of residues comprised of
only one or two amino acids, suggesting that the
primary binding site for the Ca21 is in the middle of the
peptide (Scheme I for NRDADA). We amidated the C
terminus to remove that carboxylate as a binding site.
Thus, the anchor for Ca21 binding is probably a depro-
tonated aspartic acid, but additional coordination by
other amino-acid ligands stabilizes the complex. When
C-terminal residues are involved in calcium coordina-
Figure 1. LE CAD spectrum of ESI-produced [M 2 H 1 Ca]1 ion
for Ca21/peptide complex of NRDADA.
Table 1. Majora fragment ions formed under LE CAD of ESI-produced [M 2 H 1 Ca]1
Peptide
Loss of Formation of (n 5)
H2O 2H2O NH3 H2O, NH3 y*n
y*n 2
H2O z*n
z*n 2
H2O b*n
b*n 2
H2O c*n c*n 2 H2O cn bn
NRDADGV sb — — m 6, 5 5 — — 5 — — — 2 —
GNRDADA s — — m 5 5 6 6 6 — 5 5 3 —
DRADNA s — — m — — — — 4 4 — — — —
NRDAVD s — — m 5, 4 — — — 5 — — — 2 2
NRDDAV s — — m 5, 4 5 4 — 4 — — — 2 —
DANADG s — — m — — 4 4 5 — 4 — — —
DDRANV s — — m — — 5 5 — — 4 4 — —
NRDADA s — — m 5, 4 5 — — 5 — 4 4 2 —
DENADGc s m m 5 — 5 — 5, 3 — 4 — — —
NRNADG — — m m 5 — 4 4 — — 4 — — —
NRDANG — — m w 5 — 4 — 5 — 4 4 — —
RDADGV s wb — — — — — — 4 4 3 — — —
RDADA s w — — 4 — — — 4 — 4, 3 3 — —
ANRDAD mb — s m 4 4 5 — — — 5 5 3 3
aMajor ions have relative abundances .1%. Ion designations are, for example, y*n 5 [yn 2 2H 1 Ca]
1 or b*n 5 [bn 2 2H 1 Ca]
1, where n is specified
in the table.
bRefers to ion abundances: s 5 strong, m 5 medium, and w 5 weak.
c[x3 2 2H 1 Ca]
1 also formed.
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tion (1, Scheme 1), reactions near the N terminus will
give y*n and z*n ions. On the other hand, b*n and c*n ions
are formed when N-terminal residues coordinate the
Ca21, leaving the C terminus free as a site of reaction (2,
Scheme 1). The y*n, z*n, b*n, and c*n sequence ions are
favored, whereas a*n and other ions from side-chain
cleavages do not form upon low-energy CA of calcium/
peptide complexes. For some peptides, we observed y*n
ions, for some z*n ions, and for some both. For example,
the Ca21/DDRAVN complex does not give any y*n ions
but instead produces a z*5 ion. The Ca
21/NRDAVD
complex gives y*5, y*4, but no z*n ions, and Ca
21/NRD-
DAV gives y*5, y*4, z*4, and no z*5 (Table 1). To understand
these fragmentations, we first propose structures of
calcium-bound peptides and then consider mechanisms
for precursor-ion decomposition.
For production of y*n ions, a proton may be trans-
ferred from either an a-carbon or an amide nitrogen of
the preceding residue to another amide nitrogen via a
five- or four-member ring as was proposed by Teesch
and Adams [17]. An additional source of the needed
proton in the peptides we studied is a neighboring
aspartic-acid residue. That this proton can participate in
the formation of a y*n ion was demonstrated by
Beauchamp and co-workers [24] for a highly favored
cleavage at aspartic-acid sites of [pept 1 Na]1 ions. If
this proton is removed upon binding to Ca21, then we
would expect no y*n21 ions for peptides with Asp at the
nth position from the C terminus. Examples that com-
ply with this expectation are complexes of DDRANV,
DANADG, and DRADNA, which give no y*5 ion, and
complexes of NRDADGV, DDRANV, and RDADGV,
which give no y*4 ions. An exception is DENADG, which
gives an abundant y*5 ion. This peptide contains three
amino acids with acidic side chains, whereas those that
give no y* contain only one or two. For the exception,
we propose that Ca21 is bonded, at least in part, to E
and the D in position 2 from the C terminus, leaving the
N-terminal D unbound to Ca21 and with an available
acidic proton to initiate cleavage to give y*5 (see Scheme
2). For the other peptides with two aspartic acids, both
are involved in Ca21 binding, precluding the H1 trans-
fer required to cleave the peptide bond and form the
y*n21 ion.
Formation of z*n ions also depends on the amino-acid
sequence of the peptides, and it is favored when cleav-
age takes place at aspartic-acid or asparagine residues.
For example, the calcium complex of DANADG does
not fragment to give a z*5 ion, but does give a z*4 ion,
whereas DDRANV gives z*5, but not z*4. Teesch and
Adams [17] reported that z1z ions (a more complete
description is [z 2 H 1 Ca]1z ) can form from the pre-
cursor [M 2 H 1 Ca]1 in which Ca21 is bound to any
site of the peptide chain. They proposed that the
fragmentation giving z1z product ions involves homo-
lytic cleavage of the bond between the a-carbon and the
amide nitrogen to give a distonic radical cation (Scheme
3). The a-carboxy radical site is stabilized by the reso-
nance delocalization with the carbonyl group of the
Scheme 1
Scheme 2
Scheme 3
Scheme 4
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peptide chain (Scheme IV). Because we observe z1z ions
from cleavage at residues containing carbonyl group in
the side chain, we suggest that additional resonance
stabilization of these distonic radical cation can occur. A
1,4-hydrogen atom shift interconverts the two reso-
nance hybrids of the distonic radical cation (Scheme 4).
Besides calcium-containing product ions, Ca21/pep-
tide complexes give, when activated by low-energy
collisions, unusual cn and bn ions, which do not contain
Ca21. Hu and Loo [15] previously reported nonmetal-
containing product ions from decomposition of [pep-
tide 1 Cat]21, where Cat is a transition metal ion.
Formation of ions without the Ca21 requires elimina-
tion of a doubly negative peptide fragment containing
the divalent calcium ion. The likely sites for double
deprotonation are the carboxylic groups of the aspartic-
acid side chains. Because the precursor is singly
charged, a second deprotonation is necessary and may
occur by the formation of a zwitterionic species contain-
ing a positive charge on the basic arginine residue and
a negative charge on the carboxylic group of aspartic-
acid residue. Therefore, we observe cn ions that contain
no calcium when the incipient product ion contains an
arginine and no aspartic-acid residues. For example, the
Ca21/peptide complex of NRDADGV gives a c2 ion,
whereas that of GNRDADA produces a c3 ion (Table 1).
The mechanism for the formation of the cn ions requires
bond breakage between the a-carbon and the amide
nitrogen (Scheme 5) and may proceed, as was sug-
gested by Teesch and Adams [17], either by proton
transfer from the b-carbon of the incipient neutral to the
amide nitrogen of the incipient product ion, via a
six-membered ring, or from the a-carbon to a distant
amide nitrogen. The difference in the mechanism we
propose (Scheme 5) and that of Teesch and Adams [17]
is that a metal ion is lost with the neutral, and charging
of the fragment ion is by proton transfer. Sequential
cleavage of cn ions gives bn ions. Appearance of small-
mass, noncalcium-containing ions in LE CAD spectra of
Ca21/peptide complexes is additional evidence that
calcium binding is in the center of the peptide moiety.
LE CAD of [M 1 Ca]21 ions. Doubly charged [M 1
Ca]21 ions decompose upon multiple low-energy colli-
sions in a fashion similar to that of their singly charged
counterparts. The major fragmentations are losses of
one or two water molecules and/or of ammonia (Table
2) to give doubly charged products. Although other
fragmentations of the [M 1 Ca]21 ions give both singly
and doubly charged products, there are no additional
fragmentation channels for doubly charged [M 1 Ca]21
ions beyond those of singly charged [M 2 H 1 Ca]1.
For example, the [M 1 Ca]21 of NRDADA decomposes
to give [M 2 H2O]
21, [M 2 H2O 2 NH3]
21, y*4, [y*4 2
H2O]
1, [y*4 2 2H2O]
1, (b*5)
21, (c*4)
21, [c*4 2 H2O]
21, c2,
and b2 ions (Figure 2) in a pattern that is similar to that
produced by the fragmentation of [M 2 H 1 Ca]1. One
obvious difference is that some fragment ions from
Scheme 5
Table 2. Majora fragment ions formed under LE CAD of ESI-produced [M 1 Ca]21
Peptide
Loss of Formation of (n 5)
H2O 2H2O
H2O,
NH3 y*n
y*n 2
H2O
e (y*n)
21 z*n
z*n 2
H2O (z*n)
21 b*n
b*n 2
H2O (b*n)
21 c*n
c*n 2
H2O (c*n)
21 cn bn
NRDADGV sd m — 5 5 — — — — 5 — 5 — — — 2 —
GNRDADAb s m — 4 4 — — 6 6 — — 6 — 5 5 3 —
DRADNA s — m — — — — — — 4 4 — — — — — —
NRDAVDc s m — 4 4 5 — — — — — 5 3 3 — 2 2
NRDDAV s m — 4 4 — — — — — — — — — — 3, 2 2
DANADG md wd — 4 — 5, 4 — — — — — 5 — — — — —
DDRANV s w — — — — 5 5 — — 5 — — — — —
NRDADA s — m 4 4 — — — — — — 5 — 4 4 2 2
DENADG m — — — — 5, 4 — — — — — 5 — — 4 — —
NRNADG s — m — — — 4 4 — — — — — — 4 2 —
NRDANG s — m — — — 4 4 — — — 4 — — — 2 —
RDADGV s s — — — — — — — 4 4 — — — — 1 1
RDADA s m — 4 4 — — — — — — — — — — 1 1
ANRDAD s m — — — 4 — — 5 — — 5 — — 5 3 —
aMajor ions have relative abundances . 1%. Singly charged ions do not have a charge-state designation in the symbol. Ion designations are, for
example, y*n 5 [yn 2 2H 1 Ca]
1, b*n 5 [bn 2 2H 1 Ca]
1, and (y*n)
21 5 [yn 2 H 1 Ca]
21, where n is specified in the table.
bx*5 2 H2O also formed.
c(x*5)
21 also formed.
dRefers to ion abundances: s 5 strong, m 5 medium, and w 5 weak.
ey*n 2 2H2O also formed.
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[M 1 Ca]21 remain doubly charged, whereas no such
ions are formed from [M 2 H 1 Ca]1.
Some of the [M 1 Ca]21 ions were submitted to
multiple stage decompositions (e.g., MS3 and MS4), and
no unexpected decompositions of the Ca21/peptide
complex were seen. Under MS3 and MS4, [M 1
Ca 2 H2O]
21 and [M 1 Ca 2 H2O 2 NH3]
21 ions from
NRDADA fragment by processes that are already
faintly seen in the MS/MS experiment. The fragmenta-
tions of both [M 1 Ca]21 and [M 2 H 1 Ca]1 suggest
that the metal bonding in either the neutral or the
deprotonated peptide is similar and that the metal ion
interactions with the peptide are preserved upon LE
CAD. All the calcium-containing fragment ions have
aspartic-acid or asparagine residues, and that is consis-
tent with the finding that these residues are important
in calcium-binding loops of proteins.
Although a description of the behavior of [M 1 H]1
and [M 1 2H]21 ions is beyond the scope of this article,
we make brief mention of it. LE CA of [M 1 H]1 and
[M 1 2H]21 ions gives abundant water and/or ammo-
nia losses, which are similar to the decomposition of
[M 2 H 1 Ca]1 and [M 1 Ca]21 ions. The most com-
mon ions formed upon LE CA of [M 1 H]1 and [M 1
2H]21, however, are a reasonably complete series of bn
and yn ions but no cn and zn ions.
HE CAD of FAB and ESI-Produced Ions
HE CAD of FAB-Produced Ions. Under high-energy
collisional activation, [M 2 H 1 Ca]1 complexes de-
compose to give complicated mass spectra of products
(Table 3). In contrast to LE CAD of ESI-produced ions,
HE CA of FAB-produced ions gives a series of a*n, d*n,
w*n, and v*n sequence ions. For example, the Ca
21
complex of NRDADA gives a facile water loss and a
nearly complete series of a* and c* ions (no a*1 and c*1
were seen because the mass range for data acquisition
was not set sufficiently low), d*3 and d*5 (related to the
position of aspartic-acid residues), and some b*n, z*n, and
w*n ions (Figure 3). Ions that do not contain Ca
21, c2
ions, also form under HE CA.
That the HE CAD mass spectra for alkaline-earth
metal ion complexes of peptides with aliphatic amino
acids are complicated is consistent with reports by
Figure 2. LE CAD spectrum of ESI-produced [M 1 Ca]21 ion for
Ca21/peptide complex of NRDADA.
Figure 3. HE CAD spectrum of FAB-produced [M 2 H 1 Ca]1
ion for Ca21/peptide complex of NRDADA.
Table 3. Majora fragment ions formed under HE CAD of FAB-produced [M 2 H 1 Ca]1
Peptide
Loss
of
H2O
Formation of (n 5)
x*n y*n z*n a*n b*n c*n d*n cn yn
NRDADGV sb — 5 5 4, 3, 2 2 2 5, 3 2 —
GNRDADA mb — — — 5, 2 — 6, 2 — 3 —
DRADNA m — — 2 5 4 3 5, 4, 3 — —
NRDAVD m 5 — 3 4, 3, 2 2 5, 3 5 2 —
NRDDAV s 3 3 4, 3 5, 4, 2d 3, 2 — 4, 3 2 5
DANADG m — — 4c — 3, 2 4, 2 5 — —
DDRANV m — 5, 4, 3, 2 4 5, 4, 3, 2 5, 4 4, 3, 2 5 — —
NRDADA m 5 — 2 5, 4, 3, 2 2 4, 3, 2 5 2 5
DENADG m — — — — — — — — —
NRNADG m — — — — — 4, 2 — — —
RDADGV m — 4, 3, 2 — 4, 3, 2d 4, 3, 2, 1 — — 1 —
RDADA m 2 4 3, 2 — 1 1 4, 3 1 —
ANRDAD s 5, 2 — 5 — — — 4, 3 5, 3 —
aMajor ions have relative abundances . 1%. Singly charged ions do not have a charge-state designation in the symbol. Ion designations are, for
example, y*n 5 [yn 2 2H 1 Ca]1 and (y*n)21 5 [yn 2 H 1 Ca]21, where n is specified in the table.
bRefers to ion abundances: s 5 strong, m 5 medium, and w 5 weak.
cz*4 2 H2O also formed.
da*2 2 NH2 also formed.
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Teesch and Adams [17]. They suggested that the pre-
cursor ions exist as a mixture of isomeric structures; the
peptides have more than one intrinsic metal-binding
site, and these compete for the metal. The isomeric
forms decompose to give a complicated pattern of
fragment ions. The relative abundance of a particular
product ion is determined by the stabilization of the
binding site in the precursor. In another article, Adams
and co-workers [18] reported that the metastable-ion
decompositions of negatively charged alkaline-earth
complexes of peptides containing functional side chains
(Asp, Glu, Tyr, His, and Trp) show more specific
binding. Nevertheless, the product-ion mass spectra are
still complex.
The motivation for choosing the peptides investi-
gated here is to provide a strong binding site for the
Ca21 and test the ability of collisional activation to
probe the location of that site. Although we expected
the strong intrinsic binding of Ca21 to peptides that is
revealed by LE CA, the extensive fragmentations that
were observed upon HE CA were less expected. When
high-energy collisions were used to activate ESI-pro-
duced [M 2 H 1 Ca]1 ions, the same mass-to-charge
ratio product ions arise as those formed from FAB-
produced precursors, except they are produced at lower
abundances. The internal energy of ions formed under
FAB conditions and activated by HE CA is responsible
for the extensive fragmentations. The appearance of cn
ions that do not contain Ca21 in both LE and HE CAD
spectra again is evidence that a fraction of the decom-
posing Ca21/peptide structures are similar to those
interrogated by LE CAD. But additional structures are
formed as a consequence of the greater energy depos-
ited into the complex upon HE CA. This internal energy
permits coordination of Ca21 ions by multiple peptide
sites and allows different sequence ions to form as the
metal ion moves along the peptide chain. LE CA of
ESI-produced ions, however, reveals more clearly the
specificity of Ca21 binding to these peptides.
HE CAD of ESI-produced [M 1 Ca]21 ions. Upon HE
CA, [M 1 Ca]21 ions decompose differently than when
submitted to LE CA. In addition to formation of singly
and doubly charged a*, d*, w*, and v* ions (Table 4),
losses of water and ammonia occur. Furthermore, new
losses of H2O and CO take place to give [M 1
Ca 2 46]21 upon HE activation. Although most Ca21/
peptide complexes do decompose to give sequence
ions, the relatively large size (n . 3) of the fragments
suggests that the complexation with the metal ion
prevents more complete decomposition of the precursor
ion. The neutral or charged fragments that are cleaved
from the [M 1 Ca]21 ion are of small mass, leaving
intact the preferred binding of Ca21 to the peptide. For
example, the doubly charged Ca21/peptide complex of
NRDADA fragments upon HE CA to give [M 2 H2O 1
Ca]21 of m/z 341, [M 2 H2O 2 CO 1 Ca]
21 of m/z
327, an abundant (y*5)
21 of m/z 292, a (z*5)
21 of m/z
285, and a w*2 of m/z 182 (Figure 4). The differences in
fragmentation upon LE and HE CA of ESI-produced
Figure 4. HE CAD spectrum of ESI-produced [M 1 Ca]21 ion for
Ca2 1 /peptide complex of NRDADA.
Table 4. Majora fragment ions formed under HE CAD of ESI-produced [M 1 Ca]21
Peptide
Loss of Formation of (n 5)
H2O NH3 46 x*n (x*n)
21 y*n (y*n)
21 z*n (z*n)
21 a*n (a*n)
21 b*n (b*n)
21 c*n (c*n)
21 d*n (d*n)
21 w*n
NRDADGV sb m m — — — — — 6 — 5, 4 4 — 6 — — 5 —
GNRDADA mb m m — — 6 5 6 — 6 5, 4 4 6, 4 — 5 — 6, 4 —
DRADNA m m m — — — — — — — 5 — 5 — 5 — — —
NRDAVD m m m 5 — 5 — 5 — 5, 4 — — — — — 5 — —
NRDDAV s s m 5 — 5 — 5 — 4 — 4 — 4 —— 4 —
DANADG m m m — 5, 4 — 5 — 5, 4 — 5 — — — 5 — — —
DDRANV m m m — — — — — — 5, 3 — 4 — — 5 — —
NRDADA m m m — 5 — 5 — — — — — — — — — — —
DENADG m m m — — — 4 — — — 5 — 5, 4 — — — — —
NRNADG m m m — — — 5 — — — — — — — 5, 4 — — —
NRDANG m m m — — — 5 — — — 5 — 4 — — — — —
RDADGV m m m — — — — — — — 5, 4 — — — 5 — 4 5, 4
RDADA m m m — — 4 — — — — 4 — 4 — — — 4 4
ANRDAD s m m — — 5 — 5 — — 4 — — — 4 — — 4
aMajor ions have relative abundances . 1%. Ion designations are, for example, y*n 5 [yn 2 2H 1 Ca]
1 or b*n 5 [bn 2 2H 1 Ca]
1, where n is specified
in the table.
bRefers to ion abundances: s 5 strong, m 5 medium, and w 5 weak.
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[M 1 Ca]21 ions are consistent with the concept that HE
activation deposits more energy into the complexes,
causing different and more extensive fragmentation to
occur.
Comparison of LE CAD of Mg21, Ca21, and
Ba21/Peptide Complexes
Although the types of fragmentations of metal/peptide
complexes containing either Mg21 or Ba21 ions are
nearly identical to those of complexes containing Ca21,
the relative abundances depend on the nature of the
metal ion. The trend in sizes of the metal ions is
reflected in the relative ion abundances. The ionic
radius of a Ba21 ion with a given coordination number
is greater than those of Ca21 and Mg21 with the same
coordination number. For a given peptide sequence, the
abundances of the specific N-terminal ions are high,
intermediate, and low for Mg21, Ca21, and Ba21/
peptide complexes, respectively, whereas the abun-
dances of the specific C-terminal ions are reversed:
high, intermediate, and low for Ba21, Ca21, and Mg21/
peptide complexes, respectively. For example, the [M 1
Mg]21 of ANRDAD fragments to give very abundant
[z5 2 H 1 Mg]
21 ions and low-abundance [c5 2 H 1
Mg]21 and c3 ions. On the other hand, decomposition of
the Ba21/peptide complex gives low-abundance [z5 2
H 1 Ba]21 ions but abundant [c5 2 H 1 Ba]
21 and c3
ions (Table 5). A similar trend pertains to decomposi-
tions of metal/peptide complexes as [M 2 H 1 Cat]1
ions (Table 6). When the peptide sequence is DRADNA,
an N-terminal [c4 2 2H 1 Mg 2 H2O]
1 ion dominates,
whereas an abundant C-terminal [y5 2 2H 1 Ba]
1 ion
characterizes the Ba21/peptide complex. Ca21/peptide
complexes in both cases decompose to give ions whose
abundances are intermediate to those of Mg21 and Ba21
complexes (Tables 5 and 6). The relative product-ion
abundances depend on the binding preferences of dif-
ferent metal ions. Mg21 acts as a hard acid, preferring
hard-base ligands (e.g., deprotonated carboxylic acid
groups of aspartates), whereas Ba21 behaves as a softer
acid, favoring softer carbonyl oxygen ligands and N-
terminal nitrogen ligands. Ligand preferences of Ca21
are intermediate; it is a harder acid than Ba21 but softer
than Mg21.
Conclusion
ESI-produced Ca21/peptide complexes, when submit-
ted to LE CA, undergo fragmentations that are deter-
mined by the location of the Ca21 binding site. The
nature and simplicity of the LE CAD spectra indicate
that the binding of the Ca21 ions to the peptide is to
deprotonated acid side chains and to carbonyl oxygens.
This binding involves a large fraction of the carbonyls
of these small peptides, permitting only a few low-
energy fragmentations that “trim” away the N- and/or
C-termini portions, depending on the binding site of the
peptide. The complexity of the HE CAD spectra of
FAB-produced Ca21/peptide complexes shows that ad-
ditional Ca21 binding sites become populated when the
complexes become more energized. Mg21 and Ba21 also
interact with these peptides in a qualitatively similar
way.
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